Valtech. Branding & Website.
We'll make your brand look like a million bucks. Or in the case of Valtech Cardio, $690 million.
Valtech makes Cardioband, an innovative and ingeniously effective treatment for mitral valve regurgitation (MVR), a condition in which the heart’s mitral valve doesn’t close properly, resulting in a heart that has to work a lot harder to pump blood a lot less efficiently. Existing surgical treatments required open-heart surgery, which most candidates couldn’t endure the rigors of, and the surgeon couldn’t be 100% sure of the success of the procedure until it was over because he or she was operating on a heart that had been temporarily stopped.
Valtech took existing treatments and vastly improved them. So that’s what we did with their brand and their website.
Cardioband represents an enormous leap forward in MVR treatment in two ways: first, it can be implanted into the mitral valve via an artery in the thigh, so open heart surgery is unnecessary, and second, the surgeon implanting Cardioband can operate on a beating heart, so he or she can see the impact small adjustments have on the heart’s efficiency immediately for optimal results.
Valtech needed a website as simple and powerful as the technology they pioneered
We designed a responsive site that works and looks great on whatever device it’s being viewed on. We also created brochures, conference materials and booth designs, 3D rendering work, copywriting, and the strategic position for the brand.
In the end, Valtech was purchased for $690 million.
If Valtech hadn’t seriously invested in their brand, would another company have invested $690 million in them? We like to think the branding had at least a little to do with it.
“As we continue to pursue multiple therapies to address the diverse needs of patients affected by heart valve disease, we saw an important opportunity to incorporate Valtech’s technologies into our comprehensive heart valve repair and replacement portfolio,” said Michael A. Mussallem, Edwards’ chairman and CEO. “We recognize that physicians will likely need a toolbox of options to treat their patients most effectively. We are very pleased with the progress and future prospects of the multiple internal programs we have underway, and we believe the addition of Valtech’s talented team and mitral and tricuspid technologies will present even more opportunities to help patients.”
Thanks, Valtech.
